A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines

Ann Rheum Dis. 2005 Sep;64(9):1383-4. doi: 10.1136/ard.2004.028423.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antirheumatic Agents / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunologic Factors / therapeutic use*
  • Male
  • Middle Aged
  • Practice Guidelines as Topic
  • Spondylitis, Ankylosing / drug therapy*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Turkey

Substances

  • Antirheumatic Agents
  • Immunologic Factors
  • Tumor Necrosis Factor-alpha